可能可治愈的胰腺癌:美国临床肿瘤学会临床实践指南更新
该更新仅针对2016年ASCO指南中临床问题4,即已行R0或R1切除的胰腺癌患者辅助化疗方案。基于ESPAC-4随机III期研究,专家小组修订一条推荐:吉西他滨联合卡培他滨双药方案为优选,总生存优于吉西他滨单药。
要点
- 已切除胰腺癌且未接受术前治疗者,无禁忌应接受6个月辅助化疗。
- 无毒性或耐受性担忧时,优选吉西他滨联合卡培他滨双药方案。
- 辅助治疗应在手术切除后8周内开始,前提是患者完全康复。
核心结论
- ESPAC-4研究显示,吉西他滨联合卡培他滨较吉西他滨单药改善已切除胰腺导管腺癌患者的中位总生存。
研究设计与样本
- 该更新基于ESPAC-4研究,为多中心、国际、开放标签随机对照III期试验,纳入730例可评估的已切除胰腺导管腺癌患者。
主要发现
- 双药组中位总生存为28.0个月(95%CI 23.5至31.5个月),吉西他滨单药组为25.5个月(95%CI 22.7至27.9个月),HR 0.82(95%CI 0.68至0.98;P=0.032)。
- 两组3级和4级不良事件相似,但随机分配至双药组患者的手足综合征和腹泻发生率更高。
关键数值与推荐
- 推荐所有未接受术前治疗且无医学或手术禁忌的已切除胰腺癌患者接受6个月辅助化疗。
- 无毒性或耐受性担忧时,优选吉西他滨联合卡培他滨双药方案; alternatively,可提供吉西他滨单药或氟尿嘧啶联合亚叶酸。
- 辅助治疗应在手术切除后8周内开始,前提是患者完全康复。
- 2016年ASCO原始指南的其余推荐保持不变。
临床怎么用
- 对已切除胰腺癌且未接受术前治疗者,评估禁忌后提供6个月辅助化疗。
- 无毒性或耐受性担忧时,优先选择吉西他滨联合卡培他滨双药方案。
- 若存在毒性或耐受性担忧,可提供吉西他滨单药或氟尿嘧啶联合亚叶酸。
- 辅助治疗应在手术切除后8周内开始,假设患者完全康复。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update the Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016. The October 2016 update focuses solely on new evidence that pertains to clinical question 4 of the guideline: What is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone an R0 or R1 resection of their primary tumor? Methods The recently published results of a randomized phase III study prompted an update of this guideline. The high quality of the reported evidence and the potential for its clinical impact prompted the Expert Panel to revise one of the guideline recommendations. Results The ESPAC-4 study, a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy compared gemcitabine and capecitabine with gemcitabine monotherapy in 730 evaluable patients with resected pancreatic ductal adenocarcinoma. Median overall survival was improved in the doublet arm to 28.0 months (95% CI, 23.5 to 31.5 months) versus 25.5 months (95% CI, 22.7 to 27.9 months) for gemcitabine alone (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = .032). Grade 3 and 4 adverse events were similar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients randomly assigned to the doublet arm. Recommendations All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The doublet regimen of gemcitabine and capecitabine is preferred in the absence of concerns for toxicity or tolerance; alternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered. Adjuvant treatment should be initiated within 8 weeks of surgical resection, assuming complete recovery. The remaining recommendations from the original 2016 ASCO guideline are unchanged.
引用
- Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017. PMID: 28398845. doi:10.1200/JCO.2017.72.4948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。